Philip Bedford
University of Cambridge
11 Papers
7 Citations
Philip Bedford is an academic researcher from University of Cambridge. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 10, co-authored 11 publications.
Chat about Author
Papers
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Thomas P. Monath,Farshad Guirakhoo,Richard A. Nichols,Sutee Yoksan,Robert Schrader,Christopher J. Murphy,Paul S. Blum,Stephen Woodward,Karen McCarthy,Danell Mathis,Casey Johnson,Philip Bedford +11 more
TL;DR: ChimeriVax-JE appears to be a safe vaccine that provides protective levels of neutralizing antibody after a single dose.
229
Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections
Thomas P. Monath,Karen McCarthy,Philip Bedford,Casey T Johnson,Richard Nichols,Sutee Yoksan,Ron Marchesani,Michael Knauber,Keith H Wells,Juan Arroyo,Farshad Guirakhoo +10 more
TL;DR: The safety and immunogenicity profile of ChimeriVax-JE vaccine appears to be similar to that of YF 17D, and the new vaccine holds promise for prevention of JE in travelers and residents of endemic countries.
226
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Farshad Guirakhoo,Scott Kitchener,Dennis Morrison,Remi Forrat,Karen McCarthy,Richard A. Nichols,Sutee Yoksan,Xiaochu Duan,Thomas H. Ermak,Niranjan Kanesa-thasan,Philip Bedford,Jean Lang,Marie-Jose Quentin-Millet,Thomas P. Monath +13 more
TL;DR: Surprisingly, levels of neutralizing antibodies to DEN 1, 2, and 3 viruses in YF immune subjects persisted after 1 year, and can have practical implications toward development of a dengue vaccine.
213
Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori
Stavros Sougioultzis,Cynthia K. Lee,Mazen Alsahli,Subhas Banerjee,Michel Cadoz,Robert Schrader,Bruno Guy,Philip Bedford,Thomas P. Monath,Ciaran P. Kelly,Pierre Michetti +10 more
TL;DR: In this paper, the safety and adjuvant efficacy of rectally delivered heat-labile enterotoxin (LT) together with recombinant H. pylori urease was evaluated.
57
Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial.
Casey Johnson,Thomas P. Monath,Niranjan Kanesa-thasan,Danell Mathis,Chuck Miller,Seth Shapiro,Richard A. Nichols,Karen McCarthy,Alison Deary,Philip Bedford +9 more
TL;DR: Subjects engaged in future early-stage trials of these live, attenuated vaccine against West Nile virus will be advised not to engage in contact sports or new or enhanced exerciseregimens for which they are not trained or conditioned.
11